

## ▼ Variceal Bleed Adult Panel

For patients with a suspected or confirmed variceal bleed.

For stable patients, a hemoglobin threshold of 70 g/L is recommended before initiating Packed Red Blood Cells transfusion; unstable or actively bleeding patients may need transfusion at a higher hemoglobin threshold.

Transjugular intrahepatic portosystemic shunt may be an option in some patients with refractory bleeding-suggest consult liver specialist if considering.

Inpatient Consult to Gastroenterology

EGD Procedure Order (only intended for use by prescriber who will be performing the procedure).

### Medications

#### Blood Formation, Coagulation and Thrombosis

For an elevated INR

Vitamin K: to treat supra-therapeutic INR (likely helpful only if jaundiced). Use IV only when PO is not feasible. IV administration of vitamin K is associated with hypersensitivity reactions.

vitamin K1 (phytonadione) liquid oral

10 mg, oral, daily, for 3 days

vitamin K1 (phytonadione) injection

10 mg, intravenous, daily, for 3 days

Prothrombin Complex Concentrate

#### Pro-Motility and Antibacterial

With GI bleeding, antibiotics decrease mortality, re-bleeding and sepsis. Extend duration beyond 5 days if bacteremic or other active infection. Shorten duration if discharged before 5 days.

The pro-motility properties of erythromycin can be helpful to clear the stomach of residual blood pooling before endoscopy.

erythromycin IV

3 mg/kg/dose, intravenous, once, Infuse over 45 minutes. To be given 30 to 60 minutes pre-endoscopy; coordinate with gastroscopist to ensure appropriate timing; contraindicated with QT prolongation.

cefTRIAxone IV

1 g, intravenous, daily, for 5 days

#### Gastrointestinal Agents

Until endoscopy, use proton-pump inhibitor (PPI) therapy. Intermittent PPI is equivalent to IV PPI infusions for known ulcer bleeds. Suggest PO dosing in stable patients not actively vomiting.

#### \_ pantoprazole IV or PO

pantoprazole IV

40 mg, intravenous, every 12 hours, scheduled, for 72 hours, for 72 hours post endoscopy

pantoprazole magnesium tablet enteric-coated

40 mg, oral, 2 times per day, 30 minutes before breakfast and supper, for 72 hours, for 72 hours post endoscopy

#### octreotide IV

octreotide injection 50 mcg

50 mcg, intravenous, once, today at 1500, For 1 dose

#### Followed By

octreotide 200 mcg in NaCl 0.9% 100 mL (2 mcg/mL) bag

50 mcg/hr (25 mL/hr), intravenous, at 25 mL/hr, continuous, Starting today at 1500

reassess at 72 hours. Recommend 3 to 5 days of therapy.

**I** If hepatic encephalopathy is complicating acute upper gastrointestinal bleeding (UGIB)

**lactulose liquid oral**

15-30 mL, oral, 3 times per day, as needed, hepatic encephalopathy, Titrate for 2 to 3 bowel movements per day is achieved.

**lactulose 667 mg/mL oral liquid for rectal use**

300 mL, rectal, every 6 hours, scheduled, lactulose 300 mL in 700 mL water rectally every 6 hours until clinical improvement. Retain for 30 to 60 minutes (use if intolerant of oral therapy)

**Secondary Prophylaxis (Start once hemodynamically stable. DO NOT USE WHILE ON OCTREOTIDE)**

- Secondary prophylaxis ideally requires a combination non-selective beta blockers (NSBBs) and band ligation. With refractory ascites AND severe circulatory dysfunction NSBBs are contraindicated until improvement.

- Consider starting at half dose if borderline BP/HR

- Titrate as tolerated (to heart rate 55 to 60 bpm, systolic blood pressure not below 90 mm Hg)

**nadolol tablet (Avoid if renal dysfunction as it is renally cleared)**

40 mg, oral, daily, Avoid if renal dysfunction as it is renally cleared

**propranolol tablet**

20 mg, oral, 2 times per day

**carVEDilol tablet (Avoid if decompensated (ascites). Reduces blood pressure)**

3.125 mg, oral, 2 times per day, with breakfast and supper, Avoid if decompensated (ascites). Reduces blood pressure

© 2021, Alberta Health Services, CKCM

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The license does not apply to content for which the Alberta Health Services is not the copyright owner. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Disclaimer: This material is intended for use by clinicians only and is provided on an "as is", "where is" basis. Although reasonable efforts were made to confirm the accuracy of the information, Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use.